Loading
A phase 1/2 trial of Serabelisib, Sapanisertib and Fulvestrant in advanced solid tumours, run by Faeth Therapeutics, now recruiting.
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT07558733 by Faeth Therapeutics, with 32 participants planned, started 2026-04-22 and due to reach its primary completion in 2029-05. Interventions recorded: Serabelisib, Sapanisertib and Fulvestrant.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/